Oncology / Haematology

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)

Trial Name: MK-7339-013  PI: Dr Babak Tamjid


Who can take part:

  • Patients with pathologically (histologically or cytologically) confirmed small cell lung cancer (SCLC)
  • Has limited stage small cell lung cancer (Stage I-III, by AJCC 8th Edition Cancer Staging), and can be safely treated with definitive radiation doses.
  • Has no evidence of metastatic disease by whole body PET/CT scan, CT or MRI

Exclusion criteria:

  • Has extensive stage disease, defined as stage IV (T any, N any M1a/b), or T3-4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan

For further information please contact Sally – 03 9784 7290

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4